

DISCLOSURES

InPursuit Health, LLC

Required for All Investment Instruments

The Securities and Exchange Commission requires that InPursuit Health, LLC make certain disclosures to each investor in this offering as defined in Rule 501 of Regulation D. These disclosures apply to all investment instruments offered by the Company, including Simple Agreements for Future Equity (SAFEs) and Convertible Promissory Notes.

NOTICE TO RECIPIENTS OF THIS OFFERING MEMORANDUM

1. Purpose

THIS PURPOSE OF THIS OFFERING MEMORANDUM IS TO PROVIDE INFORMATION ABOUT AN OFFER TO SELL SECURITIES OF THE COMPANY, TO A LIMITED NUMBER OF “ACCREDITED INVESTORS,” IN A MANNER DEFINED BY REGULATION D PROMULGATED BY THE SEC AND SIMILAR PROVISIONS OF APPLICABLE STATE LAWS. THE COMPANY IN ITS SOLE DISCRETION MAY ACCEPT OR REJECT ANY SUBSCRIPTION, IN WHOLE OR IN PART, AT ANY TIME PRIOR TO THE COMPLETION OF THIS OFFERING.

THIS MEMORANDUM CONTAINS ALL OF THE REPRESENTATIONS BY THE COMPANY CONCERNING THIS OFFERING, AND NO PERSON SHALL MAKE DIFFERENT OR BROADER STATEMENTS THAN THOSE CONTAINED HEREIN. INVESTORS ARE CAUTIONED NOT TO RELY UPON ANY INFORMATION NOT EXPRESSLY SET FORTH IN THIS MEMORANDUM AND TO CONSULT WITH THEIR OWN ATTORNEY(S) AND/OR INVESTMENT ADVISOR(S) PRIOR TO MAKING AN INVESTMENT IN THIS OFFERING.

2. Confidentiality

THIS MEMORANDUM IS SUBMITTED ON A CONFIDENTIAL BASIS FOR USE BY A LIMITED NUMBER OF PERSONS, WHO SHALL BE CHOSEN BY THE COMPANY, SOLELY FOR CONSIDERATION OF THE SECURITIES DESCRIBED HEREIN IN A PRIVATE PLACEMENT. THIS MEMORANDUM CONSTITUTES AN OFFER ONLY TO THE OFFEREE TO WHOM IT WAS ORIGINALLY DIRECTED. THE ACCEPTANCE OF THIS PRIVATE PLACEMENT MEMORANDUM CONSTITUTES AN AGREEMENT ON THE PART OF THE RECIPIENT HEREOF AND THE RECIPIENT’S REPRESENTATIVES TO MAINTAIN THE CONFIDENTIALITY OF THE INFORMATION CONTAINED HEREIN. DELIVERY OF THIS MEMORANDUM TO ANYONE OTHER THAN SUCH OFFEREE IS UNAUTHORIZED. THIS MEMORANDUM MAY NOT BE REPRODUCED IN WHOLE OR IN PART. THE USE OF THIS MEMORANDUM FOR ANY PURPOSE OTHER THAN AN INVESTMENT IN THE SECURITIES DESCRIBED HEREIN IS NOT AUTHORIZED AND IS PROHIBITED.

3. Non-Registration and Restrictions on Transfer of Securities

THE OFFERED SECURITIES HAVE NEITHER BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION, NOR IS SUCH REGISTRATION

CONTEMPLATED. THIS OFFERING IS BEING MADE IN THE UNITED STATES IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION PURSUANT TO RULE 506(b) OF REGULATION D UNDER THE SECURITIES ACT FOR AN OFFER AND SALE OF SECURITIES THAT DOES NOT INVOLVE A PUBLIC OFFERING. THE OFFERED SECURITIES HAVE NEITHER BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND EXCHANGE COMMISSION OR ANY STATE REGULATORY AUTHORITY, NOR HAS THE COMMISSION OR ANY STATE REGULATORY AUTHORITY PASSED UPON OR ENDORSED THE MERITS OF THE OFFERING OR THE ACCURACY OR ADEQUACY OF THIS MEMORANDUM.

THIS OFFERING OF SECURITIES IN THE COMPANY IS BEING MADE SOLELY PURSUANT TO THIS MEMORANDUM. NO PERSON HAS BEEN AUTHORIZED IN CONNECTION WITH THIS OFFERING TO GIVE ANY INFORMATION OR MAKE ANY REPRESENTATIONS OTHER THAN AS CONTAINED IN THIS MEMORANDUM AND ANY REPRESENTATION OR INFORMATION NOT CONTAINED HEREIN MUST NOT AND SHOULD NOT BE RELIED UPON AS HAVING BEEN AUTHORIZED BY THE COMPANY OR ANY OF ITS SHAREHOLDERS.

THE DISTRIBUTION OF THIS MEMORANDUM AND THE OFFER AND SALE OF THE SECURITIES IN CERTAIN JURISDICTIONS MAY BE RESTRICTED BY LAW. THIS MEMORANDUM DOES NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY IN ANY UNITED STATES STATE OR OTHER JURISDICTION TO ANY PERSON TO WHOM IT IS UNLAWFUL TO MAKE SUCH OFFER OR SOLICITATION IN SUCH STATE OR JURISDICTION. NEITHER THE DELIVERY OF THIS MEMORANDUM NOR ANY SALE MADE HEREUNDER SHALL, UNDER ANY CIRCUMSTANCES, CREATE AN IMPLICATION THAT THERE HAS BEEN NO CHANGE IN THE AFFAIRS OF THE COMPANY SINCE THE DATE HEREOF. PROSPECTIVE NON-UNITED STATES INVESTORS SHOULD INFORM THEMSELVES AS TO THE LEGAL REQUIREMENTS AND TAX CONSEQUENCES WITHIN THE COUNTRIES OF THEIR CITIZENSHIP, RESIDENCE, DOMICILE AND PLACE OF BUSINESS WITH RESPECT TO THE ACQUISITION, HOLDING OR DISPOSAL OF SECURITIES, AND ANY FOREIGN EXCHANGE RESTRICTIONS THAT MAY BE RELEVANT THERETO. THE DELIVERY OF THIS MEMORANDUM DOES NOT IMPLY THAT INFORMATION HEREIN IS CORRECT AS OF ANY TIME SUBSEQUENT TO MARCH 1, 2026. CHANGES IN APPLICABLE LAWS AND REGULATIONS COULD HAVE AN ADVERSE EFFECT ON THE PERFORMANCE OF THE COMPANY AND ON ANY INDIVIDUAL INVESTMENT IN THE COMPANY.

THE SECURITIES OFFERED HEREIN ARE “RESTRICTED.” NO SECURITIES PURCHASED AS A RESULT OF THIS OFFERING MAY BE TRANSFERRED IN THE ABSENCE OF: (1) AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT AND COMPLIANCE WITH ANY APPLICABLE STATE SECURITIES LAWS OR (2) AN OPINION OF COUNSEL IN FORM AND SUBSTANCE ACCEPTABLE TO THE COMPANY AND ITS COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE FEDERAL LAWS OR THE LAWS OF THE INVESTOR’S STATE. CONSEQUENTLY, NO PUBLIC OR OTHER MARKET FOR THE SECURITIES IS EXPECTED TO DEVELOP.

4. Risks

INVESTMENT IN A SMALL BUSINESS INVOLVES A HIGH DEGREE OF RISK, AND INVESTORS SHOULD NOT INVEST ANY FUNDS IN THIS OFFERING, UNLESS THEY CAN AFFORD TO LOSE THEIR ENTIRE INVESTMENT. IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE COMPANY AND THE TERMS OF THIS OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED.

PROSPECTIVE INVESTORS SHOULD BE AWARE THAT THEY WILL BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME.

THE SECURITIES ARE OFFERED SUBJECT TO THE RIGHT OF THE COMPANY TO REJECT ANY SUBSCRIPTION, IN WHOLE OR IN PART, IN ITS SOLE DISCRETION AND THE RIGHT TO TERMINATE THIS OFFERING AT ANY TIME.

PROSPECTIVE INVESTORS SHOULD NOT CONSTRUE THE CONTENTS OF THIS MEMORANDUM AS LEGAL, TAX, INVESTMENT OR ACCOUNTING ADVICE, AND EACH PROSPECTIVE INVESTOR SHOULD CONSULT WITH ITS OWN ADVISORS WITH RESPECT TO LEGAL, TAX, REGULATORY, FINANCIAL, ACCOUNTING AND OTHER CONSEQUENCES OF THEIR INVESTMENT IN THE COMPANY.

CERTAIN INFORMATION CONTAINED IN THIS MEMORANDUM CONSTITUTES “FORWARD-LOOKING STATEMENTS,” WITHIN THE MEANING OF SECTION 27A OF THE SECURITIES ACT AND SECTION 21E OF THE EXCHANGE ACT, WHICH CAN BE IDENTIFIED BY THE USE OF FORWARD-LOOKING TERMINOLOGY SUCH AS “MAY,” “WILL,” “SHOULD,” “EXPECT,” “ANTICIPATE,” “PROJECT,” “ESTIMATE,” “INTEND,” “CONTINUE” OR “BELIEVE” OR THE NEGATIVES THEREOF OR OTHER VARIATIONS THEREON OR COMPARABLE TERMINOLOGY. DUE TO VARIOUS RISKS AND UNCERTAINTIES, INCLUDING, WITHOUT LIMITATION, THOSE SET FORTH UNDER THE CAPTION, “RISK FACTORS,” ACTUAL EVENTS OR RESULTS OR THE ACTUAL PERFORMANCE OF THE COMPANY MAY DIFFER MATERIALLY FROM THOSE REFLECTED OR CONTEMPLATED IN SUCH FORWARD-LOOKING STATEMENTS.

THE INFORMATION CONTAINED IN THIS MEMORANDUM HAS BEEN COMPILED BY THE COMPANY AS OF THE DATE OF THIS MEMORANDUM.

[Remainder of page intentionally left blank]

INVESTOR SUITABILITY STANDARDS

This private offering is being made pursuant to Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D promulgated under the Securities Act. The offered Securities are suitable only for long-term investment by persons who have sufficient financial means to bear the risk of total loss of their investment in the Company and who have no need for liquidity in their investment. The Securities should be purchased only for investment purposes, not for short-term returns.

Accordingly, each investor will be required to represent in his or her Subscription Agreement that the purchase is for investment, for his or her account, and without any view to the sale or other disposition thereof. The Securities will be sold to persons who meet the following criteria. Either (a) the investor is (i) an “accredited investor”, as such term is defined in Rule 501(a) of Regulation D promulgated under the Securities Act and is sufficiently knowledgeable to understand the risks involved in purchasing the Securities, or (ii) the investor, or the investor through its representative, or if the investor is a corporation, partnership, limited liability company, trust or other entity, the investor, by and through its officers, directors, members, trustees, employees or other advisors, (I) is experienced in evaluating an investment in the Company, (II) has determined that an investment in the Company is a suitable investment for the investor, and (III) has such knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of the investor’s investment in the Company.

An investor will also be required to represent that it has the financial ability to bear the economic risks of its entire investment for an indefinite period, would be able to sustain a complete loss of its investment, and that it has no need for liquidity with respect to its investment in the Company. If the investor is a natural person, the investor has adequate means for providing for current needs and personal contingencies.

The suitability standards referred to above represent minimum suitability requirements for prospective investors and the satisfaction of such standards by a prospective investor does not necessarily mean that the Securities are a suitable investment for such prospective investor.

THE SUITABILITY STANDARDS DISCUSSED ABOVE REPRESENT MINIMUM SUITABILITY STANDARDS FOR PROSPECTIVE INVESTORS. EACH PROSPECTIVE INVESTOR SHOULD DETERMINE WHETHER THIS INVESTMENT IN THE COMPANY IS APPROPRIATE FOR SUCH INVESTOR.

The Company reserves the right to screen prospective investors and has the right, in its sole discretion, to reject any prospective investor for any reason or no reason.

5. Risk Factors

AN INVESTMENT IN THE COMPANY INVOLVES A HIGH DEGREE OF RISK AND IS SUITABLE ONLY FOR PERSONS OF SUBSTANTIAL FINANCIAL MEANS WHO HAVE NO NEED FOR LIQUIDITY IN THIS INVESTMENT AND WHO CAN AFFORD THE COMPLETE LOSS OF THEIR INVESTMENT.

Prospective investors should carefully consider the following risk factors, in addition to all other information set forth in this Memorandum, before making an investment decision. The risks described below are not exhaustive. Additional risks and uncertainties not currently known to the Company, or that the Company currently considers immaterial, may also materially and adversely affect the Company's business, financial condition, and results of operations. This offering involves securities that have not been registered under the Securities Act of 1933, as amended, and are being offered pursuant to an exemption from registration. There is no guarantee that any investor will realize a return on this investment.

A. Risks Related to the Company and Its Business

1. **Early Stage of Development; No Assurance of Profitability.** The Company is at an early stage of development. The Company may have limited operating history, limited revenues, and may not yet have a proven business model. There is no assurance that the Company will ever achieve profitability or generate sufficient revenues to sustain its operations. The Company's prospects must be considered in light of the risks, expenses, and difficulties frequently encountered by companies in their early stages of development, particularly those in the healthcare industry. The Company may be required to raise additional capital in the future and there is no assurance that such capital will be available on acceptable terms, or at all. If the Company is unable to raise additional capital, it may be required to curtail or cease operations entirely.
2. **Risk of Total Loss of Investment.** Investors should be prepared for the possibility of losing their entire investment. Unlike investments in established companies with proven track records, an investment in an early-stage company involves a substantial risk of total loss. The Company cannot guarantee that investors will receive any return of capital, and investors should not invest funds they cannot afford to lose.
3. **Dependence on Key Personnel.** The Company's success depends to a significant degree upon the continued services and performance of its founder and key management personnel, including its Chief Executive Officer. The loss of the services of any key person could have a material adverse effect on the Company's business, financial condition, and results of operations. The Company may not have key-person life insurance in place and may be unable to attract or retain qualified replacement personnel. At this stage of the Company's development, the departure of any key employee could be irreplaceable in the near term and could jeopardize the Company's ability to execute its business plan.
4. **Uncertainty of Financial Projections and Forward-Looking Statements.** Any financial projections, forecasts, or forward-looking statements provided by the Company are based on assumptions that may prove to be incorrect. Actual results may differ materially from any projections provided. Such projections are inherently speculative and

no representation is made that projected results will be achieved. Investors should not rely on any projections in making their investment decision and should instead conduct their own independent analysis of the Company's business and prospects.

1. **Need for Additional Financing; Dilution.** The Company anticipates that it will require substantial additional financing in the future to fund its operations, product development, and growth strategy. The Company may issue additional SAFEs, convertible notes, preferred units, or other equity or debt securities in the future. Such future issuances may be on terms more favorable than those offered to current investors and will result in dilution to existing investors. There is no assurance that the Company will be able to obtain additional financing on terms acceptable to the Company, or at all.
2. **Competition.** The healthcare industry is highly competitive. The Company faces competition from established companies with substantially greater financial resources, larger sales and marketing organizations, more extensive research and development capabilities, and broader name recognition than the Company. Competitors may develop products or services that are superior to, less expensive than, or more effectively marketed than those of the Company. There is no assurance that the Company will be able to compete successfully or maintain or increase its market share.

B. Risks Related to the Healthcare Industry and Regulation

1. **Extensive Government Regulation.** The healthcare industry is subject to extensive and frequently changing federal and state regulation. The Company's operations may be subject to laws and regulations administered by, among others, the U.S. Food and Drug Administration (FDA), the Department of Health and Human Services (HHS), the Centers for Medicare and Medicaid Services (CMS), and various state licensing and regulatory bodies. Failure to obtain or maintain required regulatory approvals, licenses, or certifications could prevent or delay the Company from operating its business or require it to cease operations in certain jurisdictions. Changes in applicable laws or regulations, or in their interpretation or enforcement, could increase the Company's costs of compliance or adversely affect its operations in ways the Company cannot currently predict.
2. **HIPAA and Privacy Regulation.** To the extent the Company handles protected health information (PHI), it is subject to the Health Insurance Portability and Accountability Act of 1996 (HIPAA), the Health Information Technology for Economic and Clinical Health Act (HITECH), and related state privacy laws. Compliance with these regulations is complex and costly. A data breach, failure to maintain adequate safeguards, or violation of applicable privacy laws could result in significant civil and criminal penalties, reputational damage, and loss of business. The regulatory environment surrounding health data privacy continues to evolve, and new or amended regulations could require the Company to incur significant additional costs.
3. **Reimbursement and Insurance Coverage Uncertainty.** Revenue from the Company's products or services may depend in part on coverage and reimbursement by third-party payors, including private insurers and government programs such as Medicare and Medicaid. There is no assurance that the Company's offerings will be eligible for reimbursement, that reimbursement rates will be adequate to support a profitable

business, or that existing reimbursement coverage will not be reduced or eliminated. Healthcare reform legislation, regulatory changes, or shifts in payor policies could adversely affect the Company's ability to generate revenue from insured patients or customers.

4. **Healthcare Reform and Policy Risk.** The U.S. healthcare system is subject to ongoing legislative and regulatory reform at the federal and state levels. Changes to the Affordable Care Act, Medicare, Medicaid, or other federal and state health programs could materially alter the market for the Company's products or services, affect pricing, or change the competitive landscape in ways that could harm the Company's business. The Company cannot predict the nature, timing, or scope of such changes, and any such changes could have a material adverse effect on the Company's operations and financial results.

C. Risks Related to the Securities and This Offering

1. **Conversion May Never Occur.** The Securities offered by the Company, including SAFEs and Convertible Promissory Notes, convert into equity only upon the occurrence of specified events, such as a qualifying Equity Financing, Liquidity Event, or Dissolution Event. There is no guarantee that any such event will occur within a specific timeframe or at all. If the Company does not raise additional equity capital, is not acquired, does not complete an IPO, and does not dissolve, these instruments may remain outstanding for an extended period without converting and without generating any return for the investor. SAFE investors should note that SAFEs do not bear interest and have no maturity date, meaning investors have no right to demand repayment. Convertible Note investors should note that while notes accrue interest and have a maturity date, repayment at maturity is subject to the Company's ability to pay, and there is no assurance the Company will have sufficient assets to satisfy its repayment obligation.
2. **Illiquidity of the Investment.** There is no public market for any Securities offered by the Company, and no such market is expected to develop. All Securities are subject to significant restrictions on transfer. As a result, investors may be unable to sell or otherwise liquidate their investment for an indefinite period of time, or at all. Investors should be prepared to hold this investment for an extended period and should not invest funds needed for near-term liquidity.
3. **No Voting or Governance Rights Prior to Conversion.** Prior to conversion into equity, investors holding SAFEs and Convertible Notes are not members of the Company and have no voting rights with respect to Company decisions. Investors cannot veto transactions, prevent dilutive financings, or compel the Company to take any action. The Company's founders and management retain full decision-making authority over the Company's business and affairs prior to conversion. Information rights are limited to annual unaudited financial statements and quarterly updates at the Company's discretion as described in the applicable Subscription Agreement.
4. **Valuation Cap May Not Reflect Actual Company Value.** The Post-Money Valuation Cap of \$25,000,000, applicable to both SAFEs and Convertible Notes, is set for purposes of calculating the Conversion Price and does not represent a determination by the Company or any independent third party of the Company's actual fair market value. The

Company's actual value at the time of any conversion event may be higher or lower than the Valuation Cap. If the Company raises its next equity round at a pre-money valuation higher than the Valuation Cap, investors will benefit from the cap; however, if the Company raises at a valuation below the Valuation Cap, investors will convert at the lower financing price, which could result in a less favorable outcome than anticipated.

5. **Subordination to Existing Preferred Return.** As disclosed in the Subscription Agreement, one existing investor in the Company holds Class B membership units with a 1x preferred return. In any Dissolution Event or Liquidity Event, the Class B unitholder's preferred return will be satisfied prior to distributions to SAFE and Convertible Note holders, to the extent the Company's proceeds are sufficient. This preferred return could reduce the amounts available for distribution to investors and could, in a low-proceeds scenario, result in investors receiving less than their invested capital or nothing at all.
6. **Instrument-Specific Risks.** Each investment instrument carries specific risks: (a) SAFEs have no maturity date, do not accrue interest, and may remain outstanding indefinitely without generating any return; the investor has no right to demand repayment at any time. (b) Convertible Promissory Notes are debt instruments that accrue interest at 5% per annum and mature 18 months from issuance; however, repayment at maturity is subject to the Company's ability to pay, and there is no assurance the Company will have sufficient assets to satisfy its repayment obligation at maturity. If the Company is unable to repay the note at maturity, the investor's recourse may be limited. Investors should carefully review the terms of their specific instrument and consult with their own advisors.

D. General Investment Risks

1. **No Independent Verification of Information.** The information contained in this Memorandum has been prepared by the Company and has not been independently verified by any third party. No independent auditors, investment bankers, or other advisors have been retained to verify the accuracy or completeness of the information provided. Prospective investors are encouraged to conduct their own independent due diligence and to consult with their own legal, tax, and financial advisors before making an investment decision.
2. **Tax Risks.** The tax treatment of SAFEs and Convertible Promissory Notes, and any securities received upon conversion, is complex and may be subject to change. There is limited IRS guidance on the treatment of SAFEs for federal income tax purposes, and state tax treatment may differ. Investors could face unexpected tax liability in connection with holding their Securities, upon conversion, or upon a subsequent sale of securities received upon conversion. Each investor should consult with a qualified tax advisor regarding the tax consequences specific to their situation before investing.
3. **Macroeconomic and Market Conditions.** The Company's business and the value of this investment may be adversely affected by general economic conditions, including inflation, interest rate changes, recessionary conditions, reduced access to capital markets, and declining consumer confidence. Unfavorable macroeconomic conditions could reduce demand for the Company's products or services, make it more difficult to raise additional financing, delay or prevent a liquidity event, or reduce the value of the

Company at the time of any conversion event. These risks are beyond the control of the Company and the investors.

4. **Cybersecurity Risks.** The Company's operations rely on technology systems and may involve the storage and transmission of sensitive data, including health-related information. The Company faces risks from cyberattacks, data breaches, ransomware, and system failures. Healthcare companies are frequent targets of cybercriminals due to the sensitivity of health data. A significant cybersecurity incident could result in regulatory penalties, litigation, reputational harm, and costs of remediation that could materially affect the Company's financial condition and operations.
5. **Intellectual Property Risk.** The Company may rely on trade secrets, proprietary know-how, patents, trademarks, or other intellectual property to protect its competitive position. There is no assurance that any pending or future patent or trademark applications will be approved, that existing intellectual property protections will provide adequate competitive barriers, or that the Company's intellectual property will not be challenged, invalidated, or infringed by third parties. Intellectual property litigation is expensive and time-consuming, and an adverse outcome could materially harm the Company's business. In addition, the Company may be subject to claims by others that the Company's activities infringe upon their intellectual property rights.

THE FOREGOING RISK FACTORS ARE NOT EXHAUSTIVE. PROSPECTIVE INVESTORS SHOULD CAREFULLY CONSIDER THESE AND OTHER RISKS BEFORE INVESTING. EACH INVESTOR SHOULD CONSULT WITH INDEPENDENT LEGAL, TAX, AND FINANCIAL ADVISORS BEFORE MAKING AN INVESTMENT DECISION. THE COMPANY MAKES NO REPRESENTATION THAT THE INVESTMENT IS SUITABLE FOR ANY PARTICULAR INVESTOR.